Amagase H, Murakami T, Misaki M, Higashi Y, Ushijima M, Fuwa T, Yata N
Institute of Pharmaceutical Sciences, Hiroshima University School of Medicine, Japan.
Life Sci. 1990;47(12):1031-6. doi: 10.1016/0024-3205(90)90475-7.
The protective effect of human epidermal growth factor (hEGF) on the gastric mucosal lesions in rats was examined in relation to the immunoreactive concentration of plasma. Human EGF (30 micrograms/kg) was administered intravenously, intraperitoneally or subcutaneously. At different times following the administration of hEGF, rats received acidified ethanol solution to induce an experimental gastric mucosal lesion. Sum of lesion length in the gastric mucosa was used as a lesion index. Human EGF administered parenterally markedly decreased the gastric mucosal lesions in 10 min after administration of necrotizing solution, and 10 to 30 min delay was observed in the development of maximal protective action. Profiles of protective potency against the hEGF dose administered intraperitoneally or subcutaneously 30 min before administration of necrotizing solution revealed that the effective dose of hEGF (ED50) was about 5.2 and 2.6 micrograms/kg, for intraperitoneal and subcutaneous administrations, respectively.
研究了人表皮生长因子(hEGF)对大鼠胃黏膜损伤的保护作用及其与血浆免疫反应性浓度的关系。将人表皮生长因子(30微克/千克)静脉内、腹腔内或皮下注射给药。在给予hEGF后的不同时间,给大鼠注射酸化乙醇溶液以诱导实验性胃黏膜损伤。胃黏膜损伤长度总和用作损伤指数。经肠道外给予人表皮生长因子后,在给予坏死溶液10分钟后可显著减轻胃黏膜损伤,且在最大保护作用出现前有10至30分钟的延迟。在给予坏死溶液前30分钟腹腔内或皮下注射hEGF的剂量-保护效力曲线表明,腹腔内和皮下注射hEGF的有效剂量(ED50)分别约为5.2微克/千克和2.6微克/千克。